[
  {
    "ts": "2026-01-30T07:07:17+00:00",
    "headline": "EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)",
    "summary": "Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found […]",
    "url": "https://finance.yahoo.com/news/epkinly-trial-results-prompt-price-070717523.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "dcc30dec-20dc-3cb2-a486-98d6c9ff3ed1",
      "content": {
        "id": "dcc30dec-20dc-3cb2-a486-98d6c9ff3ed1",
        "contentType": "STORY",
        "title": "EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)",
        "description": "",
        "summary": "Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found […]",
        "pubDate": "2026-01-30T07:07:17Z",
        "displayTime": "2026-01-30T07:07:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/02fcbbad2abad8b764e699aa3a675314",
          "originalWidth": 640,
          "originalHeight": 427,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dNNfiqZU0wSeWAqQUW_1yg--~B/aD00Mjc7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/02fcbbad2abad8b764e699aa3a675314.cf.webp",
              "width": 640,
              "height": 427,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xk2.Is4xMYeWQc.GTH.r4A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/02fcbbad2abad8b764e699aa3a675314.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/epkinly-trial-results-prompt-price-070717523.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/epkinly-trial-results-prompt-price-070717523.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "GNMSF"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]